Helius Medical Technologies, Inc. Announces Participation of Oregon Health & Science University in its Therapeutic Experience Program
Helius Medical Technologies (Nasdaq: HSDT) announced the addition of Oregon Health & Science University to its Therapeutic Experience Program, aiming to evaluate the effects of PoNS therapy for gait improvement in patients with multiple sclerosis (MS). The study is a multi-center, open-label trial to assess adherence to the PoNS device combined with physical therapy. Enrollment is expected to start in Q4 2022, targeting 50-60 MS patients across 10-12 Centers of Excellence in the U.S. Key endpoints include maintenance of gait improvement and overall functional outcomes.
- OHSU's participation enhances the credibility of the study given its status as a leading MS treatment center.
- The trial aims to gather valuable data on adherence to PoNS therapy, potentially improving treatment outcomes for MS patients.
- Dependence on securing contracts with rehabilitation clinics for the PoNS device may pose challenges.
- Future enrollment and participation are uncertain due to potential impacts from the COVID-19 pandemic.
-- Third Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate the impact of subjects’ adherence to PoNS® therapy for gait improvement in Multiple Sclerosis --
NEWTOWN, Pa., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the addition of Oregon Health & Science University (“OHSU”) to its Therapeutic Experience Program (TEP). This initiative will be led by Vijayshree Yadav, MD, MCR, FANA, FAAN, Professor of Neurology and OHSU Multiple Sclerosis Center Director. OHSU joins several other Centers of Excellence in this company-sponsored open-label observational trial designed to evaluate the impact of subjects’ adherence to Portable Neuromodulation Stimulator (PoNS) therapy in patients with multiple sclerosis (MS).
“The OHSU Multiple Sclerosis Center is one of the top programs in the country for the treatment and care of MS and we’re thrilled about the Center’s participation to our TEP. Dr. Yadav and her team are at the forefront of research in understanding and treating MS, and their involvement will go a long way in helping us understand the relationship between adherence to PoNS therapy and a meaningful therapeutic outcome,” said Antonella Favit-Van Pelt, M.D., Ph.D., Helius' Chief Medical Officer.
“With the availability of new technologies and therapies, it’s an exciting time in the research and treatment of MS. Studies have shown that the brain can make new connections after injury and rehabilitation can reduce functional disability, increasing a patient’s independence. A significant portion of MS patients suffer from gait deficit and PoNS therapy provides a unique opportunity to improve gait functionality and mobility. We’re excited to partner with Helius on this important initiative,” said Dr. Yadav.
About Oregon Health & Science University
Oregon Health & Science University is Oregon's only academic health center and distinguished nationally as a research university dedicated solely to advancing health sciences. OHSU focuses on discoveries to prevent and cure diseases, on education that prepares the health care and health science professionals of the future, and on patient care that incorporates the latest advances.
About the Therapeutic Experience Program
The Therapeutic Experience Program (“TEP”) is a Helius-sponsored, open label observational, interventional multi-center outcome research trial designed to assess adherence to on-label PoNS therapy for improvement in gait deficits for patients with multiple sclerosis (“MS”) in a real-world clinical setting. The study will rate subjects’ adherence to PoNS therapy, which combines the PoNS device with physical therapy, to better understand the relationship between adherence to the treatment regimen and therapeutic functional outcome. The primary endpoint of the study is maintenance of gait improvement from the end of supervised therapy (Phase 1) to the end of unsupervised therapy (Phase 2) in relation to the subject’s adherence to PoNS therapy. The secondary endpoint is improvement of gait and balance deficit over time and clinical global impression of change.
The study will be conducted at ten to twelve Centers of Excellence across the United States, with an estimated four PoNS devices per site. Enrollment is expected to begin in the fourth quarter of 2022 and continue into 2023. A total of fifty to sixty patients with MS are expected to take part in the progra
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brain’s ability to compensate and promotes neuroplasticity, aiming to improve the lives of people dealing with neurologic diseases. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS). For more information, visit www.heliusmedical.com.
About the PoNS Device and PoNS Therapy
The Portable Neuromodulation Stimulator (PoNS) is an innovative non-surgical medical device, inclusive of a controller and mouthpiece, which delivers electrical stimulation to the surface of the tongue to improve balance and gait. The PoNS device is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (“MS”) and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only. Helius is advancing PoNS post-approval research in MS through a recently launched Therapeutic Experience Program (TEP) designed to partner with neurologists and neurorehabilitation therapists at 10-12 US centers of excellence, who express an interest in becoming “early adopters” of PoNS therapy. For more information visit www.ponstherapy.com to learn more.
PoNS is also authorized for sale in Canada for two indications: (i) for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used in conjunction with physical therapy; and (ii) for use as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy. PoNS is also authorized for sale in Australia for short term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gai
Cautionary Disclaimer Statement
Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as “believe,” “expect,” “continue,” “will,” “goal,” “aim” and similar expressions. Such forward-looking statements include, among others, statements regarding expected enrollment, patient participation and other details of the TEP study and the ability of key opinion leaders in the management of MS to build their knowledge of PoNS® therapy and advise the broader medical community.
There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include uncertainties associated with the Company’s capital requirements to achieve its business objectives, the impact of the COVID-19 pandemic, the Company’s ability to train physical therapists in the supervision of the use of the PoNS Treatment, the Company’s ability to secure contracts with rehabilitation clinics, the Company’s ability to obtain national Medicare coverage and to obtain a reimbursement code so that the PoNS device is covered by Medicare and Medicaid, the Company’s ability to build internal commercial infrastructure, secure state distribution licenses, build a commercial team and build relationships with Key Opinion Leaders, neurology experts and neurorehabilitation centers, market awareness of the PoNS device, future clinical trials and the clinical development process, manufacturing and supply chain risks, the product development process and FDA regulatory submission review and approval process, other development activities, ongoing government regulation, and other risks detailed from time to time in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, and its other filings with the United States Securities and Exchange Commission and the Canadian securities regulators, which can be obtained from either at www.sec.gov or www.sedar.com.
The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law.
Investor Relations Contact
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
FAQ
What is the goal of the PoNS therapy trial announced by Helius Medical Technologies?
When is enrollment expected to begin for the HSDT PoNS therapy trial?
How many patients will participate in the HSDT PoNS therapy study?
Which institution joined Helius Medical Technologies' Therapeutic Experience Program?
What are the primary endpoints of the PoNS therapy study?
